|
1
|
Paez JG, Jänne PA, Lee JC, et al: EGFR
mutations in lung cancer: Correlation with clinical response to
gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lynch TJ, Bell DW, Sordella R, et al:
Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to
gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rodenhuis S, van de Wetering ML, Mooi WJ,
Evers SG, van Zandwijk N and Bos JL: Mutational activation of the
K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of
the lung. N Engl J Med. 317:929–935. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pao W, Wang TY, Riely GJ, et al: KRAS
mutations and primary resistance of lung adenocarcinomas to
gefitinib or erlotinib. PLoS Med. 2:e172005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Soda M, Choi YL, Enomoto M, et al:
Identification of the transforming EML4-ALK fusion gene in
non-small-cell lung cancer. Nature. 448:561–566. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stephens P, Hunter C, Bignell G, et al:
Lung cancer: Intragenic ERBB2 kinase mutations in tumours. Nature.
431:525–526. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Naoki K, Chen TH, Richards WG, Sugarbaker
DJ and Meyerson M: Missense mutations of the BRAF gene in human
lung adenocarcinoma. Cancer Res. 62:7001–7003. 2002.PubMed/NCBI
|
|
8
|
Pao W and Girard N: New driver mutations
in non-small-cell lung cancer. Lancet Oncol. 12:175–180. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shigematsu H and Gazdar AF: Somatic
mutations of epidermal growth factor receptor signaling pathway in
lung cancers. Int J Cancer. 118:257–262. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Suda K, Tomizawa K and Mitsudomi T:
Biological and clinical significance of KRAS mutations in lung
cancer: An oncogenic driver that contrasts with EGFR mutation.
Cancer Metastasis Rev. 29:49–60. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vogelstein B and Kinzler KW: Cancer genes
and the pathways they control. Nat Med. 10:789–799. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Weir BA, Woo MS, Getz G, et al:
Characterizing the cancer genome in lung adenocarcinoma. Nature.
450:893–898. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dahabreh IJ, Linardou H, Kosmidis P,
Bafaloukos D and Murray S: EGFR gene copy number as a predictive
biomarker for patients receiving tyrosine kinase inhibitor
treatment: a systematic review and meta-analysis in non-small-cell
lung cancer. Ann Oncol. 22:545–552. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dahabreh IJ, Linardou H, Siannis F,
Kosmidis P, Bafaloukos D and Murray S: Somatic EGFR mutation and
gene copy gain as predictive biomarkers for response to tyrosine
kinase inhibitors in non-small cell lung cancer. Clin Cancer Res.
16:291–303. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cappuzzo F, Hirsch FR, Rossi E, et al:
Epidermal growth factor receptor gene and protein and gefitinib
sensitivity in non-small-cell lung cancer. J Natl Cancer Inst.
97:643–655. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hirsch FR, Varella-Garcia M, Cappuzzo F,
et al: Combination of EGFR gene copy number and protein expression
predicts outcome for advanced non-small-cell lung cancer patients
treated with gefitinib. Ann Oncol. 18:752–760. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Soh J, Okumura N, Lockwood WW, et al:
Oncogene mutations, copy number gains and mutant allele specific
imbalance (MASI) frequently occur together in tumor cells. PLoS
ONE. 4:e74642009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sasaki H, Hikosaka Y, Kawano O, Moriyama
S, Yano M and Fujii Y: Evaluation of Kras gene mutation and copy
number gain in non-small cell lung cancer. J Thorac Oncol. 6:15–20.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wagner PL, Perner S, Rickman DS, et al: In
situ evidence of KRAS amplification and association with increased
p21 levels in non-small cell lung carcinoma. Am J Clin Pathol.
132:500–505. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gandhi J, Zhang J, Xie Y, et al:
Alterations in genes of the EGFR signaling pathway and their
relationship to EGFR tyrosine kinase inhibitor sensitivity in lung
cancer cell lines. PLoS One. 4:e45762009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shigematsu H, Lin L, Takahashi T, et al:
Clinical and biological features associated with epidermal growth
factor receptor gene mutations in lung cancers. J Natl Cancer Inst.
97:339–346. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yamamoto H, Shigematsu H, Nomura M, et al:
PIK3CA mutations and copy number gains in human lung cancers.
Cancer Res. 68:6913–6921. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Toyooka S, Maruyama R, Toyooka KO, et al:
Smoke exposure, histologic type and geography-related differences
in the methylation profiles of non-small cell lung cancer. Int J
Cancer. 103:153–160. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Broet P, Dalmasso C, Tan EH, et al:
Genomic profiles specific to patient ethnicity in lung
adenocarcinoma. Clin Cancer Res. 17:3542–3550. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ichihara S, Toyooka S, Fujiwara Y, et al:
The impact of epidermal growth factor receptor gene status on
gefitinib-treated Japanese patients with non-small-cell lung
cancer. Int J Cancer. 120:1239–1247. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cote ML, Haddad R, Edwards DJ, et al:
Frequency and type of epidermal growth factor receptor mutations in
African Americans with non-small cell lung cancer. J Thorac Oncol.
6:627–630. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Reinersman JM, Johnson ML, Riely GJ, et
al: Frequency of EGFR and KRAS mutations in lung adenocarcinomas in
African Americans. J Thorac Oncol. 6:28–31. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Leidner RS, Fu P, Clifford B, et al:
Genetic abnormalities of the EGFR pathway in African American
patients with non-small-cell lung cancer. J Clin Oncol.
27:5620–5626. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tsao AS, Tang XM, Sabloff B, et al:
Clinicopathologic characteristics of the EGFR gene mutation in
non-small cell lung cancer. J Thorac Oncol. 1:231–239.
2006.PubMed/NCBI
|
|
30
|
Ho C, Murray N, Laskin J, Melosky B,
Anderson H and Bebb G: Asian ethnicity and adenocarcinoma histology
continues to predict response to gefitinib in patients treated for
advanced non-small cell carcinoma of the lung in North America.
Lung Cancer. 49:225–231. 2005. View Article : Google Scholar : PubMed/NCBI
|
